Mark A. Socinski, MD, executive medical director at AdventHealth Cancer Institute, recommends immediate comprehensive molecular testing at the time of lung cancer diagnosis. Stating that oncogenic driver mutation identification is essential to effective targeted therapies, Dr. Socinski suggests complementary testing of both tissue and blood samples for the most comprehensive approach.

Learn more by clicking here.